Geographic Atrophy (GA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 Geographic atrophy (GA) is defined as the late stage of the dry form of age-related macular degeneration (AMD). Some patients with age-related macular degeneration (AMD) may develop geographic atrophy (GA), which refers to regions of the retina where cells waste away and die (atrophy). The edge of GA was recognized as the termination of continuous RPE. Internal to the edge, there was an absence of RPE cells over wide areas, although a few RPE cells were scattered over the area of GA. The first visible alterations of AMD are drusen and retinal pigment epithelial (RPE) irregularities. This early stage of age-related maculopathy (ARM) may progress to either geographic atrophy (GA) or exudative AMD. Approximately 11% of patients with atrophic AMD eventually progress to the exudative form at four years of evolution. In some eyes with choroidal neovascularisation (CNV) also leads to GA.

·       In the USA, the prevalence of GA is 3.5% in subjects older than 65 years, accounting for approximately half the prevalence of exudative AMD.

Thelansis’s “Geographic Atrophy (GA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Geographic Atrophy (GA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Geographic Atrophy (GA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Geographic Atrophy (GA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Geographic Atrophy (GA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033